Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Gene therapy for B cell lymphomas

A K Fielding1, S J Russell

  • 1Cambridge University Department of Haematology.

Cancer Surveys
|January 1, 1997
PubMed
Summary
This summary is machine-generated.

Gene therapy holds future promise for B cell lymphomas, with ongoing research in adoptive immunotherapy and vaccination. Strategies focus on immune modulation, suicide genes, and drug resistance for enhanced cancer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PIWIs, piRNAs and Retrotransposons: Complex battles during reprogramming in gametes and early embryos.

Reproduction in domestic animals = Zuchthygiene·2017
Same author

High somatic mutation and neoantigen burden are correlated with decreased progression-free survival in multiple myeloma.

Blood cancer journal·2017
Same author

Clinical presentation and outcomes in light chain amyloidosis patients with non-evaluable serum free light chains.

Leukemia·2017
Same author

Pomalidomide-dexamethasone in refractory multiple myeloma: long-term follow-up of a multi-cohort phase II clinical trial.

Leukemia·2017
Same author

Prognostic implications of abnormalities of chromosome 13 and the presence of multiple cytogenetic high-risk abnormalities in newly diagnosed multiple myeloma.

Blood cancer journal·2017
Same author

Natural history of t(11;14) multiple myeloma.

Leukemia·2017
Same journal

Future directions: bladder cancer.

Cancer surveys·2004
Same journal

Radiotherapy and chemotherapy for invasive bladder cancer.

Cancer surveys·2004
Same journal

The role of surgery in the multimodality treatment of bladder cancer.

Cancer surveys·2004
Same journal

Clonal development of bladder cancer and its relevance to the clinical potential of HLA antigen and TP53 based gene therapy.

Cancer surveys·2004
Same journal

Clinical evaluation of immunotherapy: are there differences between papillary and flat in situ bladder cancer?

Cancer surveys·2004
Same journal

Molecular biological changes in bladder cancer.

Cancer surveys·2004
See all related articles

Area of Science:

  • Oncology
  • Immunology
  • Genetics

Background:

  • B cell lymphomas represent a significant therapeutic challenge.
  • Current gene therapy strategies for these malignancies are largely in preclinical development.
  • Adoptive immunotherapy and idiotypic vaccination show clinical promise.

Purpose of the Study:

  • To review current and emerging gene therapy approaches for B cell lymphomas.
  • To highlight the potential of immune modulation and targeted gene delivery.
  • To discuss the requirements for successful gene transfer and expression.

Main Methods:

  • Review of preclinical and early clinical studies in gene therapy for B cell lymphomas.
  • Analysis of strategies including immune modulation, suicide gene therapy, and chemoprotection.

Related Experiment Videos

  • Discussion of gene transfer efficiency and targeting.

    • Main Results:

    • Adoptive immunotherapy and idiotypic vaccination demonstrate clinical potential.
    • In vitro and animal studies support immune system-based therapeutic strategies.
    • Gene therapy approaches include T cell modulation, direct tumor cell targeting, suicide genes, and drug resistance genes.

    Conclusions:

    • Gene therapy is poised to play a significant future role in treating B cell lymphomas.
    • Efficient and accurate gene transfer with correct expression is crucial for therapeutic success.
    • Targeted gene delivery is a key area of active research for advancing these therapies.